on Parmantier & Cie. GmbH
PARMANTIER & CIE. Updates on CLINUVEL Pharmaceuticals Strategy
Frankfurt am Main, February 25, 2025 – PARMANTIER & CIE. has released an update on CLINUVEL Pharmaceuticals Ltd.'s strategic realignment, emphasizing targeted expansion and accelerated development processes. The company focuses on key clinical projects to improve market penetration and enterprise value despite a challenging macroeconomic environment.
CLINUVEL's updated strategy highlights further development of SCENESSE® for vitiligo, ACTH, and EPP, while deprioritizing less advanced projects. Additionally, the launch of the "PhotoCosmetics" line marks a significant business model expansion, with CYACÊLLE Radiant set for market introduction in 2025, followed by more products in 2026. This shift into non-pharmaceutical sectors anticipates unlocking new growth avenues.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Parmantier & Cie. GmbH news